Valuation: Inovio Pharmaceuticals, Inc.

Market Cap 102M 91M 84.34M 76.74M 145M 9.72B 147M 1.01B 398M 5.07B 384M 376M 16.16B P/E 2026 *
-1.23x
P/E 2027 * -2.27x
Enterprise Value 102M 91M 84.34M 76.74M 145M 9.72B 147M 1.01B 398M 5.07B 384M 376M 16.16B EV / Sales 2026 *
154x
EV / Sales 2027 * 2.02x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day-4.80%
1 week-13.90%
Current month-18.84%
1 month-18.17%
3 months-11.60%
6 months-16.80%
Current year-43.10%
1 week 0.95
Extreme 0.95
1.18
1 month 0.95
Extreme 0.95
1.34
Current year 0.56
Extreme 0.5632
2.03
1 year 0.56
Extreme 0.5632
2.72
3 years 0.56
Extreme 0.5632
14.75
5 years 0.56
Extreme 0.5632
93.24
10 years 0.56
Extreme 0.5632
405.48
Manager TitleAgeSince
Chief Executive Officer 60 2022-05-09
Director of Finance/CFO 62 2002-05-31
Chief Tech/Sci/R&D Officer 60 2022-06-26
Director TitleAgeSince
Chairman 81 2019-01-02
Director/Board Member 66 2017-12-31
Director/Board Member 68 2020-01-14
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/26 Free

Director

76,000 0.0928%
5/20/26 Exercice

Chief Technology Officer

75,817 0.0925%
5/20/26 Free

Chairman

76,000 0.0928%
Change 5-day change 1-year change 3-year change Capi.($)
-4.80%-13.90%-57.87%-83.16% 102M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -1.97%-1.71%+35.18%+76.57% 37.25B
Weighted average by Cap. -2.20%-0.50%+44.22%+96.48%

Financials

2026 *2027 *
Net sales 667K 593K 549K 500K 943K 63.27M 958K 6.6M 2.59M 33.02M 2.5M 2.45M 105M 50.61M 44.98M 41.69M 37.93M 71.58M 4.8B 72.73M 501M 196M 2.51B 190M 186M 7.99B
Net income -68.03M -60.47M -56.05M -51M -96.23M -6.46B -97.77M -674M -264M -3.37B -255M -250M -10.74B -56.49M -50.21M -46.54M -42.34M -79.9M -5.36B -81.18M -559M -219M -2.8B -212M -207M -8.92B
Net Debt - -
Projected Income Statement - Annual - Inovio Pharmaceuticals, Inc.
Logo Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Employees
112
Date Price Change Volume
26-10-16 US$0.9901 -4.80% 2,056,045
26-10-15 US$1.040 +5.48% 1,760,172
26-10-14 US$0.9860 -1.22% 3,001,337
26-10-13 US$0.9982 -9.67% 8,473,007
26-10-12 US$1.105 -3.91% 2,330,477
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Inovio Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.9901USD
Average target price
3.167USD
Spread / Average Target
+219.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Inovio Pharmaceuticals, Inc.